Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: thin (200), weaken (39), water down (204), reduce (1000), attenuate (9), weak (45)

HSCTAlemtuzumabBusulphan-12-Fludarabine-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-BUSULFAN (12 doses)-FLUDARABINE-METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) CONDITIONING This regimen will only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabBusulphan-12-Fludarabine-VUD-Methotrexate-GvHD.pdf

HSCTAlemtuzumabBusulphan-10-Fludarabine-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-BUSULFAN (10 doses)-FLUDARABINE-METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) CONDITIONING This regimen will only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabBusulphan-10-Fludarabine-VUD-Methotrexate-GvHD.pdf

HSCTAlemtuzumabBusulphan-08-Fludarabine-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-BUSULFAN (8 doses)-FLUDARABINE-METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) CONDITIONING This regimen will only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabBusulphan-8-Fludarabine-VUD-Methotrexate-GvHD.pdf

Inotuzumab Ozogamicin

Description: Relapsed or refractory CD22-positive B-Cell acute lymphoblastic leukaemia.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Inotuzumab-Ozogamicin.pdf

DVd_Twice weekly_Daratumumab-Bortezomib-Dexamethasone_Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (twice weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (twice weekly)-Daratumumab-Dexamethasone Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Twice-weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

Isatuximab VRD weekly

Description: Chemotherapy Protocol Myeloma Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20) Regimen Myeloma – Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Isatuximab-VRD-weekly-Ver1.pdf

Daratumumab

Description: Chemotherapy Protocol Myeloma Daratumumab Regimen • Myeloma – Daratumumab monotherapy Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and refractory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab.pdf

Bowel preparation for your child's colonoscopy - patient information

Description: This factsheet explains how to prepare your child's bowel before a colonoscopy.
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Bowel-preparation-for-your-childs-colonoscopy-2737-PIL.pdf

BV-CHP Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Ver1

Description: Chemotherapy Protocol LYMPHOMA BRENTUXIMAB VEDOTIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE (BV-CHP) Regimen • Lymphoma – Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Indication Brentuximab vedotin in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BV-CHP-Brentuximab-vedotin-cyclophosphamide-doxorubicin-prednisolone.pdf

DA_3+8_CADD

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA Ambulatory Regimen AmB - DA (3+8) CADD–Cytarabine-Daunorubicin Regimen • Acute Myeloid Leukaemia – AmB - DA (3
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-3-8-CADD.pdf

1 to 10 of 77

Previous 1 2 3 4 5 … Next